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Mandelic acid is a chiral metabolite of the industrial pollutant styrene and is used in chemical skin peels, 
as a urinary antiseptic and as a component of other medicines. In humans, S-mandelic acid undergoes 
rapid chiral inversion to R-mandelic acid by an undefined pathway but it has been proposed to proceed 
via the acyl-CoA esters, S- and R-2-hydroxy-2-phenylacetyl-CoA, in an analogous pathway to that for 
Ibuprofen. This study investigates chiral inversion of mandelic acid using purified human recombinant 10 
enzymes known to be involved in the Ibuprofen chiral inversion pathway. Both S- and R-2-hydroxy-2-
phenylacetyl-CoA were hydrolysed to mandelic acid by human acyl-CoA thioesterase-1 and -2 (ACOT1 
and ACOT2), consistent with a possible role in the chiral inversion pathway. However, human α-
methylacyl-CoA racemase (AMACR; P504S) was not able to catalyse exchange of the α-proton of S- and 
R-2-hydroxy-2-phenylacetyl-CoA, a requirement for chiral inversion. Both S- and R-2-phenylpropanoyl-15 
CoA were epimerised by AMACR, showing that it is the presence of the hydroxy- group that prevents 
epimerisation of R- and S-2-hydroxy-2-phenylacetyl-CoAs. The results show that it is unlikely that 2-
hydroxy-2-phenylacetyl-CoA is an intermediate in the chiral inversion of mandelic acid, and that the 
chiral inversion of mandelic acid is via a different pathway to that of Ibuprofen and related drugs. 
Introduction 20 
Mandelic acid (2-hydroxy-2-phenylacetic acid 1) is a common 
chiral α-hydroxyacid produced from styrene, a hazardous 
monomer used in the plastics industry.1, 2 During its metabolism, 
styrene is converted to phenyloxirane (styrene epoxide) by 
CYP2E1, the majority of which is ring opened to 1-phenylethane-25 
1,2-diol (styrene glycol) by epoxide hydrolase. The latter is 
oxidised to mandelic acid and 2-oxo-2-phenylacetic acid 
(phenylglyoxylic acid).1, 3-5 Both 1-phenylethane-1,2-diol and 
mandelic acid 1 are excreted in the urine and monitoring of their 
levels is used to assess environmental exposure to styrene,6, 7 30 
whilst 2-oxo-2-phenylacetic acid has been shown to induce 
striatal-motor toxicity in rats.8 Mandelic acid 1 is also used 
pharmaceutically in α-hydroxyacid chemical skin peels for the 
treatment of acne, scarring and hyperpigmentation9 and in urinary 
antiseptics and bladder irrigants.10 It is also a component of or 35 
used in the manufacture of anti-viral agents,10-12 contraceptives13 
and cyclic peptides.14 Thioesters of mandelic acid have been 
investigated as inhibitors of glyoxylase 1 for the treatment of 
cancer15 and glycosides containing mandelic acid have also been 
shown to possess anti-tumour activity.16  40 
 Mandelic acid 1 has long been known to undergo chiral 
inversion during its metabolism. In bacteria, bi-directional chiral 
inversion is catalysed by the Mg2+-dependent mandelate racemase 
to produce a racemic mixture from either enantiomer.17-19 In 
mammals, mandelic acid 1 undergoes uni-directional chiral 45 
inversion of the S-enantiomer to form the R-enantiomer.3, 4, 6 Gao 
et al.6 proposed that chiral inversion of S-mandelic acid 1S 
occurred by a three step pathway (Scheme 1), analogous to that 
for Ibuprofen and other 2-arylpropanoic acid (2-APA) drugs,20-22 
consisting of: formation of S-2-hydroxy-2-phenylacetyl-CoA 2S 50 
by an acyl-CoA synthetase (Step 1); epimerisation to R-2-
hydroxy-2-phenylacetyl-CoA 2R by α-methylacyl-CoA racemase 
(AMACR) via a deprotonated (enolate) intermediate (Step 2); and 
hydrolysis of R-2-hydroxy-2-phenylacetyl-CoA 2R to R-mandelic 
acid 1R by an acyl-CoA thioesterase (ACOT) (Step 3). This 55 
pathway6 was proposed based on the structural similarities 
between mandelic acid 1 and Ibuprofen 3, in that both 
compounds possess an aromatic side-chain and a chiral centre 
adjacent to the carboxylic acid. S-2-Hydroxy-2-phenylacetyl-CoA 
2S was rapidly hydrolysed and R-mandelic acid 1R formed in rat 60 
liver cell extracts,6 but conversion of 2S to 2R was not proven.  
 
Scheme 1 The proposed chiral inversion pathway for mandelic acid 1. 
ACOT, acyl-CoA thioesterase; AMACR, α-methylacyl-CoA racemase. 
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 The chiral inversion pathway of Ibuprofen 3R and other 2-
APA drugs (Scheme 2) is well-established.20-22 Only R-Ibuprofen 
3R is converted into R-Ibuprofenoyl-CoA 4R, by long-chain fatty 
acyl-CoA synthetase (Step 1),23-25 which undergoes R- to S- chiral 
inversion.20 Chiral inversion of R-Ibuprofenoyl-CoA 4R is 5 
catalysed by α-methylacyl-CoA racemase (AMACR) (Step 2),20, 
21, 26, 27 whilst hydrolysis of the S-Ibuprofenoyl-CoA product 4S is 
probably catalysed by acyl-CoA thioesterase-1 (ACOT1) (Step 
3).22 The pathway necessitates transport of 4R from the cytosol 
into mitochondria or peroxisomes where AMACR is localised,28-10 
30 followed by export of 4S to the cytosol for hydrolysis.20, 22  
 
Scheme 2 The chiral inversion pathway of Ibuprofen 3 and other 2-APA 
drugs. ACOT, acyl-thioesterase; AMACR, α-methylacyl-CoA racemase. 
 This paper reports an in vitro study on the chiral inversion of 15 
mandelic acid 1 using recombinant human AMACR and ACOT 
enzymes to determine if chiral inversion can occur by the same 
pathway as for Ibuprofen 3. The results show that 2-hydroxy-2-
phenylacetyl-CoA 2 is not a substrate for AMACR, and hence 
chiral inversion of mandelic acid 1 occurs by a different pathway 20 
to Ibuprofen 3. 
Results and Discussion 
 Chiral inversion of mandelic acid 1 is from the S-enantiomer to 
the R-enantiomer (Scheme 1).4, 6 This uni-directional chiral 
inversion of mandelic acid from 1S to 1R in mammalian cells 25 
implies a multi-step chiral inversion pathway in which either 
activation of S-mandelic acid 1S or production of R-mandelic 
acid 1R is stereospecific. That of Ibuprofen 3 and related drugs is 
from the R-enantiomer to the S-enantiomer (Scheme 2),20 i.e. the 
stereochemical direction of chiral inversion is opposite for the 30 
two pathways. The direction of chiral inversion for Ibuprofen 3 is 
known to be determined by the requirement of long-chain fatty 
acyl-CoA synthetase for substrates with R- configuration.23-25 
 A number of potential acyl-CoA substrates were required in 
order to test whether mandelic acid 1 chiral inversion was 35 
mediated by the Ibuprofen 3 pathway. Gao et al.6 synthesised 
racemic 2-hydroxy-2-phenylacetyl-CoA esters 2 by reaction of 
phenylglyoxal with CoA-SH followed by treatment with 2,6-
dimethylpyridine.15 In this study a stereoselective synthesis of 2 
was developed (Scheme 3A) as the efficiency of conversion of 40 
ACOT substrates is known to be influenced by the epimeric 
configuration at the 2-position.22 Direct reaction of mandelic acid 
1R or 1S with carbonyldiimidazole did not yield the expected 
product, and therefore a direct synthesis of 2R and 2S was not 
possible. The hydroxy groups of mandelic acid 1R or 1S were 45 
therefore protected using TBDMS-Cl in a known procedure to 
give the chiral TBDMS ethers 5R and 5S.14 These were treated 
with carbonyldiimidazole to give the activated acids 6R and 6S. 
Treatment of 6R and 6S with CoA-SH followed by deprotection 
with KF gave the desired epimeric acyl-CoA esters 2R and 2S. 50 
Acidification of the TBDMS-protected acyl-CoA esters 7R and 
7S was necessary to prevent base-catalysed hydrolysis of the 
acyl-CoA ester upon treatment with KF. R- and S-2-
phenylpropanoyl-CoAs 8R and 8S were also synthesised 
(Scheme 3B) in order to compare the influence of 2-hydroxy vs. 55 
2-methyl groups. Direct reaction of 2-phenylpropanoic acid 9R 
and 9S with carbonyldiimidazole21 gave the activated acids 10R 
and 10S, which were treated with CoA-SH to give 8R and 8S. 
Myristoyl-CoA 11 was synthesised as a known substrate of 
ACOT1 and ACOT2,22 and ±-Fenoprofenoyl-CoA as a known 60 
substrate of AMACR.21 
 
Scheme 3 Synthesis of substrates. A. S-2-Hydroxy-2-phenylacetyl-CoA 
2S; B. S-2-Phenylpropanoyl-CoA 8S. Reagents and conditions: i. 
TBDMS-Cl, imidazole, THF, 4°C, 1 hour, then 1.0 M NaOH aq., 105 65 
mins; ii. Carbonyldiimidazole, dichloromethane, room temp., 45 mins; iii. 
CoA-SH, tri-lithium salt, THF/aq. 0.1 M NaHCO3 (1:1), room temp, >16 
h; iv. HCl to pH ~3.5, KF, 18 h. R-2-Hydroxy-2-phenylacetyl-CoA 2R 
and R-2-phenylpropanoyl-CoA 8R were synthesised by identical routes 
from R-mandelic acid 1R and R-2-phenylpropanoic acid 9R, respectively. 70 
 Conversion of these acyl-CoA substrates by selected enzymes 
involved in the Ibuprofen chiral inversion pathway was then 
investigated. AMACR is known to catalyse epimerisation of 2-
APA-CoA substrates, and is localised in mitochondria and 
peroxisomes28-30 and was selected for study. ACOT1 is localised 75 
in the cytosol31 and is thought to be the primary enzyme 
responsible for hydrolysis of 2-APA-CoA esters to their 
corresponding acids.22 ACOT2 is located in mitochondria31 and 
has been implicated in toxicities of 2-APA drugs, so was also 
selected for study. Long-chain fatty acyl-CoA synthetase 80 
(Ibuprofenoyl-CoA synthetase24) was not selected for study as its 
stereochemical requirements23-25 are inconsistent with the 
direction of mandelic acid 1 chiral inversion.3, 4, 6 
 Selected acyl-CoA esters were tested as substrates with 
ACOT1 and ACOT2. Both enzymes were active with their 85 
known substrate, myristoyl-CoA 11.22, 32 The 2-hydroxy-2-
phenylacetyl-CoA (2S and 2R) and 2-phenylpropanoyl-CoA (8S 
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and 8R) esters were then tested as substrates. All of these acyl-
CoA esters were hydrolysed to their corresponding acids and 
CoA-SH, as judged by the increasing absorbance at 412 nm due 
to reaction of CoA-SH with DTNB. No hydrolysis above 
background was observed in negative controls containing heat-5 
inactivated enzyme, thus showing that the reaction was enzyme-
catalysed. These results are consistent with the observation that 
both 2S and 2R were hydrolysed in rat liver cell extracts.6  
 Kinetic parameters for each of the substrates were then 
determined (Table 1 and 2). Substrates 11, 2S and 8S showed 10 
substrate inhibition, whilst 2R and 8R showed standard 
Michaelis-Menten behaviour. The 2-hydroxy-2-phenylacetyl-
CoA (2S and 2R) and R-2-phenylpropanoyl-CoA (8R) esters 
were modest substrates for ACOT1 and ACOT2 compared to 
myristoyl-CoA 11, as judged by kcat/Km values. 2-Hydroxy-2-15 
phenylacetyl-CoA 2S was converted somewhat more efficiently 
than 2R by both ACOT1 and ACOT2, as judged by kcat/Km 
values. Kinetic plots show that data for 8S fitted the substrate 
inhibition model (Supplementary Information) for both enzymes, 
but yielded unreasonable kinetic parameters. 20 
 
Table 1 Kinetic parameters ± SE for ACOT1. Ki values are reported for 
those substrates showing uncompetitive substrate inhibition.  
Substrate Km (µM) Vmax  
(nmol.min-1.mg-1) 
Ki (µM) kcat (s
-1) kcat/Km  
(s-1 M-1) 
11 84 ± 170 68 ± 119 28 ± 69 0.054 646 
2S 156 ± 138 75 ± 56 40 ± 38 0.060 386 
2R 62 ± 18 12 ± 1.5 None 0.010 159 
8S >>10,000 >>10,000 0.11 - - 
8R 22 ± 5.7 5.0 ± 0.4 None 0.004 179 
Table 2 Kinetic parameters ± SE for ACOT2. Ki values are reported for 
those substrates showing uncompetitive substrate inhibition. 25 
Substrate Km (µM) Vmax  
(nmol.min-1.mg-1) 
Ki (µM) kcat (s
-1) kcat/Km  
(s-1 M-1) 
11 29 ± 11 15 ± 10 152 ± 205 0.027 1703 
2S 172 ± 199 103 ± 104 27 ± 32 0.094 549 
2R 131 ± 37 20 ± 3 None 0.018 142 
8S >>10,000 >>10,000 0.11 - - 
8R 5.3 ± 0.3 27 ± 5 None 0.005 178 
  
 2-Hydroxy-2-phenylacetyl-CoA (2S and 2R) and 2-
phenylpropanoyl-CoA (8S and 8R) esters were then tested as 
substrates for purified human recombinant AMACR by assaying 
for exchange of the α-proton with deuterium.21, 26 Under the 30 
reaction conditions the best known AMACR substrate, ±-
Fenoprofenoyl-CoA,21 showed >95% conversion (as measured by 
conversion of the 2-methyl group signal from a doublet into a 
single peak, a 1:1:1 triplet J = ~1 Hz, by 1H NMR spectroscopy). 
Assays for 8S and 8R, conducted in parallel under identical 35 
conditions, resulted in ~60% conversion of S-2-phenylpropanoyl-
CoA 8S, and ~40% conversion of R-2-phenylpropanoyl-CoA 8R. 
Exchange was not observed in negative controls containing heat-
inactivated enzyme. Exchange of the α-proton is an obligatory 
step in the epimerisation reaction catalysed by AMACR,20, 21, 26 40 
and hence it is highly likely that chiral inversion of 8S and 8R 
also occurred. 
 Assays of 2S and 2R were also carried out with AMACR 
under identical conditions. As expected, control experiments 
showed that exchange of the α-proton of ±-Fenoprofenoyl-CoA 45 
occurred with live enzyme but not heat-inactivated enzyme. The 
α-proton singlets of 2S and 2R at ca. 5.3 p.p.m. in the 1H NMR 
spectra were unchanged when assays containing active enzyme 
and heat-inactivated controls were compared (Figure 1). 
Integration of the adenosine CH proton at 6.0 p.p.m. and the 50 
mandelic acid α-proton at ca. 5.3 p.p.m. showed they had a 
constant near 1:1 ratio, with no reduction of signal upon 
incubation with active AMACR. A reduction in the intensity of 
the α-proton signal of 2R and 2S would be expected if significant 
exchange for deuterium had occurred. This result demonstrates 55 
that R- and S- 2-hydroxy-2-phenylacetyl-CoA 2R and 2S do not 
undergo significant α-proton exchange. Since removal of the α-
proton is an obligatory first step in the AMACR epimerisation 
reaction,20, 21, 26 it can be concluded that 2R and 2S are not 
epimerised.  60 
 
Figure 1 1H NMR spectra of 2R incubated with AMACR, showing α-
proton at ca. 5.3 p.p.m. Left panel, heat-inactivated enzyme; Right panel, 
live enzyme, showing no reduction in signal.  
 The failure of 2R and 2S to be epimerised by AMACR is not 65 
due to them having insufficiently hydrophobic phenyl side-
chains, as evidenced by the significant levels of α-proton 
exchange with the 2-phenylpropanoyl-CoA substrates, 8S and 
8R. The substrates 2R and 2S differ from 8R and 8S only in 
having 2-hydroxy or 2-methyl substituents, respectively. The 70 
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hydroxyl and methyl substituents are of similar size but are 
hydrophilic (hydroxy group) and hydrophobic (methyl group), 
respectively. No X-ray crystal structure for human AMACR has 
been reported, but structures for the highly similar M. 
tuberculosis homologue have been reported.33-35 In this enzyme 5 
the substrate methyl side-chain is accommodated in a 
hydrophobic pocket, comprising of methylene groups from the 
side-chains of His-126, Asp-127, Asn-152, Asp-156, and Leu-
217, Tyr-224 and Ile-240 of the second subunit35 (residue 
numbers refer to MCR). These residues are identical in human 10 
AMACR 1A, corresponding to His-122, Asp-123, Asn-148, Asp-
152, Leu-213, Tyr-220, Ile-236 (Supplementary Figure S1). Thus, 
it appears that 2R and 2S will be substantially excluded from the 
enzyme as a result of the hydrophilic 2-hydroxy group been 
unable to occupy the hydrophobic methyl group binding pocket. 15 
 An alternative possibility is that the presence of the 2-hydroxy 
group inhibits formation of the enolate intermediate20, 21, 26 in the 
reaction catalysed by AMACR. The pKa of mandelic acid 1 has 
been measured as 22 (for formation of the enol),36 compared to a 
pKa value of ~21 for the α-proton of acyl-CoA esters.37 The α-20 
proton of 2-hydroxy-2-phenylacetyl-CoAs 2R and 2S are likely to 
be more acidic than in mandelic acid 1, suggesting that an enolate 
could be formed upon binding. This again supports the idea that 
lack of metabolism of 2R and 2S is due to lack of binding within 
the AMACR active site. 25 
 There are a number of alternative metabolic pathways where 
2S and 2R could undergo chiral inversion. One possibility is that 
chiral inversion of 2-hydroxy-2-phenylacetyl-CoA substrates 2R 
and 2S is mediated by an alternative 2-methylacyl-CoA 
racemase/epimerase. The only other enzyme of this type in 30 
humans is 2-methylmalonyl-CoA epimerase, which catalyses a 
chiral inversion step during the metabolism of propionyl-CoA to 
succinyl-CoA. 2-Methylmalonyl-CoA epimerase utilises a 
catalytic metal ion17, 38, 39 in a similar fashion to bacterial 
mandelate racemase.17-19 However, the relative positions of the 35 
carboxylate ligand in methylmalonyl-CoA and the hydroxyl 
group in 2-hydroxy-2-phenylacetyl-CoA 2 are different. Citrate, 
an analogue of the 2-methylmalonyl-CoA substrate, ligates to the 
active site metal ion of methylmalonyl-CoA epimerase using two 
carboxylate ligands and not its carboxylate and hydroxy 40 
ligands,38 showing the importance of the relative positions of 
these ligating groups. Thus, it is unlikely that 2-hydroxy-2-
phenylacetyl-CoA 2 will be able to bind to 2-methylmalonyl-CoA 
epimerase in a manner which is competent for catalysis. 
 A second possibility is that 2S is metabolised by derivatisation 45 
of the hydroxy group. These derivatives are unlikely to be 
accommodated within the active site of AMACR, based on 
structural models of the related MCR enzyme.33-35 The 2-methyl 
binding pocket in MCR from M. tuberculosis can only 
accommodate small groups,34 and it is likely that any 50 
modification of 2S (e.g. by acetylation) would exclude substrates 
by steric hindrance. Similarly, these derivatives of 2S are unlikely 
to be able to bind to 2-methylmalonyl-CoA epimerase in a way 
which is competent for catalysis since chelation to the active site 
metal will be further compromised. 55 
 A further aspect to be considered is the requirement for acyl-
CoA formation in order for the proposed pathway (Scheme 1) to 
occur. Long-chain fatty acyl-CoA synthetase is known to be 
specific for R-APAs,23-25 whilst activation of S-mandelic acid is 
required. Furthermore, there is no evidence that long-chain fatty 60 
acyl-CoA synthetase is able to activate 2-hydroxy-fatty acids. 
Thus, the involvement of this specific enzyme in the mandelic 
acid 1 chiral inversion pathway can be excluded based on these 
stereochemical and other considerations. However, at least 26 
acyl-CoA synthetase enzymes are present in the human 65 
genome,40 so potentially an alternative enzyme may be able to 
catalyse the required conversion of S-mandelic acid 1S to S-2-
hydroxy-2-phenylacetyl-CoA 2S. Conversion of racemic long-
chain 2-hydroxyfatty acids to their corresponding acyl-CoA 
esters by an undefined acyl-CoA synthetase has been 70 
demonstrated in rat liver and mouse brain extracts.41, 42 Activation 
of mandelic acid 1 has not been specifically studied, but naturally 
occurring long-chain 2-hydroxyfatty acids substrates are the D-
isomer, possessing R-stereochemistry. Activation of racemic 2-
hydroxyfatty acids has also been observed, suggesting that the 75 
enzyme may be non-stereoselective.41 These observations are 
inconsistent with the known direction of mandelic acid chiral 
inversion (S to R). 3, 4, 6  
Conclusions 
Mandelic acid 1 is component of a number of drugs9, 10 and drugs 80 
in development10-14 and is a marker of environmental exposure to 
styrene.1-5 Its chiral inversion pathway is of interest in order to 
understand the metabolism of these xenobiotics. Although 
mandelic acid 1 and Ibuprofen 3 have superficially similar 
structures, the results in this paper demonstrate that they are not 85 
metabolised by the same pathway. This conclusion is reached 
based on AMACR being unable to catalyse α-proton exchange of 
2S or 2R and therefore it cannot catalyse the required 
epimerisation reaction. As a consequence, different enzymes 
must be involved in the chiral inversion step of the two pathways. 90 
It is also unlikely that chiral inversion of 2S or 2R can be 
performed by 2-methylmalonyl-CoA epimerase or that 
epimerisation of a derivative with a modified 2-hydroxy group 
could be performed by either enzyme, and this implies that chiral 
inversion of mandelic acid 1 probably does not proceed via an 95 
acyl-CoA intermediate at all (as shown in Scheme 1).  
 Moreover, this study demonstrates that ACOT1 and ACOT2 
can hydrolyse both epimers of 2-hydroxy-2-phenylacetyl-CoA 2, 
and hence cannot determine the direction of chiral inversion for 
the proposed pathway as a whole. Metabolism via an acyl-CoA 100 
intermediate6 therefore requires stereospecific conjugation of S-
mandelic acid with CoA-SH to form S-2-hydroxy-2-phenylacetyl-
CoA 2S. The acyl-CoA synthetases which activate 2-
hydroxyfatty acids appear to be either specific for substrates with 
R-configuration or are non-stereospecific.41 These stereochemical 105 
observations are inconsistent with the observed direction of 
mandelic acid 1 chiral inversion for the pathway as a whole (2S 
to 2R),3, 4, 6 and further argue for separate pathways.  
 Chiral inversion of mandelic acid 1 by stereoselective 
oxidation and reduction is an obvious alternative pathway which 110 
does not involve acyl-CoA intermediates. This possibility has 
been investigated, and stereoselective oxidation of S-mandelic 
acid 1S by NAD+-dependent dehydrogenases has been 
observed.43 S-mandelic acid has also been shown to be 
stereoselectively oxidised by the kidney isoform, but not the liver 115 
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isoform, of rat L-2-hydroxyacid oxidase.44 Chiral inversion of 
mandelic acid 1 has been observed in rat liver homogenates,6 
implying that L-2-hydroxyacid oxidase cannot be involved. The 
oxidation product in this alternative pathway is 2-oxo-2-
phenylacetate (phenylglyoxylic acid). Previous studies4 have 5 
shown that the majority of 2-oxo-2-phenylacetate is not reduced 
in vivo to mandelic acid 1 (in rats), with only around 1% of the 
total substrate been converted. Moreover, the reduction reaction 
appears not to be completely stereoselective, with a reported ratio 
of products of ca. 9:1 (1R: 1S). Other studies have reported that 10 
metabolism of S-mandelic acid 1S is stimulated by NADPH,45 
implying that reduction could take place under some 
circumstances. The exact pathway for mandelic acid chiral 
inversion therefore remains unclear. 
Experimental 15 
General Experimental 
All chemicals were obtained from the Sigma-Aldrich Chemical 
Co. or Fisher Scientific Ltd and were used without further 
purification, unless otherwise noted. Reagents were of analytical 
grade or equivalent (synthesis) or biochemical grade. Oasis HLB 20 
cartridges were obtained from Waters Corporation. Myristoyl-
CoA 11 and ±-Fenoprofenoyl-CoA were synthesised as 
previously described.21, 22 Reactions were performed at ambient 
temperature, unless otherwise stated. Solvents were evaporated 
under reduced pressure. NMR spectra were recorded on Bruker 25 
Avance III 400.04 MHz or 500.13 MHz spectrometers. Chemical 
shifts are reported to the nearest 0.01 p.p.m. and coupling 
constants (J values) are reported to 0.1 Hz. Multiplicities of peaks 
are described as follows: s, singlet; d, doublet; t, triplet; m, 
multiplet. Mass spectra were obtained using VG7070E and 30 
Bruker microTOF spectrometers in the ES+ mode at the 
University of Bath Mass Spectrometry Service. Solutions in 
organic solvents were dried over anhydrous magnesium sulfate 
and evaporated under reduced pressure. Aqueous solutions were 
prepared in 18.2 Mega-Ω.cm-1 Nanopure water and pH adjusted 35 
with HCl or NaOH solutions as appropriate. Construction of 
expression plasmids for human AMACR26 and ACOT1 and 
ACOT222 have been previously described. E. coli BL21 (DE3) 
pLysS and Rosetta2 (DE3) expression strains were obtained from 
Novagen. 40 
Synthesis of S-mandelic acid O-TBDMS ether 5S14 
TBDMS-Cl (331 mg, 2.2 mmol, 2.2 eq.) and imidazole (163 mg, 
2.4 mmol, 2.4 eq.) were added to a solution of S-mandelic acid 1S 
(152 mg, 1.0 mmol) in anhydrous THF (3 mL) cooled to 4 ̊C and 
the reaction mixture was stirred for 1 h. The reaction was allowed 45 
to warm to room temperature and stirred for a further 3 h before 
filtration and concentration in vacuo. NaOH (1.0 M, 3 mL) was 
added and the mixture stirred for 105 minutes before dilution 
with 3 mL water. The reaction was extracted with diethyl ether (2 
x 5 mL), and the reaction mixture acidified to pH ~3.5 with 1.0 M 50 
citric acid buffer, pH 3.5 and extracted with diethyl ether (3 x 5 
mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated to give 5S as a colourless solid (230 mg, 
86 %): 1H NMR (400.04 MHz, CDCl3)14 δ 9.30 (br s, 1H), 7.49-
7.28 (m, 5H), 5.22 (s, 1H), 0.92 (s, 9H), 0.12 (s, 3H), 0.00 (s, 55 
3H). 
Synthesis of R-mandelic acid O-TBDMS ether 5R 
The title compound was synthesised from 1R (152 mg, 1.0 mmol) 
by the same method to give 5R (232 mg, 87 %). NMR data was 
identical to 5S.  60 
Synthesis of S-2-hydroxy-2-phenylacetyl-CoA 2S 
5S (58 mg, 0.22 mmol) was dissolved in anhydrous 
dichloromethane (2 mL) and stirred with carbonyldiimidazole (71 
mg, 0.44 mmol, 2.0 eq.) for 45 minutes. The reaction was 
extracted with water (5 x 5 mL), dried over MgSO4, filtered and 65 
concentrated to dryness. The residue was dissolved in THF (2 
mL) and aq. NaHCO3 (0.1 M, 2 mL) and stirred with reduced 
coenzyme A, tri-lithium salt (20 mg, 0.025 mmol) for >16 h. The 
reaction mixture was diluted with water (1 mL), acidified to pH 
~3.5 with 1 M HCl and stirred with anhydrous KF (27 mg, 0.46 70 
mmol) for 18 h. The mixture was extracted with diethyl ether (5 x 
5 mL) and freeze-dried. The product 2S was purified by solid-
phase extraction using an Oasis HLB cartridge. After loading the 
cartridge was washed with water (3 mL) and eluted with 
water/acetonitrile (4:1, 7 mL). The elution fraction was 75 
concentrated in vacuo and freeze-dried to give 2S as a colourless 
solid (4.3 mg): 1H NMR (500.13 MHz, D2O) δ 8.45 (s, 1H), 8.15 
(s, 1H), 7.41-7.24 (m, 5H), 6.07 (d, 1H, J= 7.0 Hz), 5.24 (s, 1H), 
4.20-4.08 (m, 2H), 3.94-3.87 (m, 2H), 3.82 (dd, 1H, J= 9.5, 4.2 
Hz), 3.44 (dd, 1H, J= 9.5, 4.3 Hz), 3.30-3.10 (m, 4H), 3.06-2.85 80 
(m, 2H), 2.20-2.07 (m, 2H), 0.75 (s, 3H), 0.63 (s, 3H); HRMS 
(EI) Calcd. for C29H40N7O18P3SNa: 922.1267, Found: 922.1240. 
Synthesis of R-2-hydroxy-2-phenylacetyl-CoA 2R 
The title compound was synthesised from 5R (40 mg, 0.15 mmol) 
by the same method to give 2R (3.0 mg). NMR and other data 85 
were identical to 2S. 
Synthesis of S-2-phenylpropanoyl-CoA 8S 
9S (30 mg, 0.20 mmol) was dissolved in dichloromethane (2 mL) 
and stirred with carbonyldiimidazole (65 mg, 0.40 mmol) for 45 
minutes. The reaction was extracted with water (5 x 5 mL), dried 90 
over MgSO4, filtered and concentrated to dryness. The residue 
was dissolved in THF (2 mL) and aq. NaHCO3 (0.1 M, 2 mL) and 
stirred with coenzyme A, tri-lithium salt (16 mg, 0.02 mmol) for 
>16 h. The reaction mixture was diluted with water (1 mL) and 
acidified to pH ~3.5 with 1 M HCl. The mixture was extracted 95 
with diethyl ether (5 x 5 mL) and freeze-dried. The product was 
purified by solid-phase extraction using an Oasis HLB cartridge. 
After loading, the cartridge was washed with water (3 mL) and 
eluted with water/acetonitrile (1:1, 7 mL). The elution fraction 
was concentrated in vacuo and freeze-dried to give 8S as a 100 
colourless solid (2.0 mg): 1H NMR (500.13 MHz, D2O) δ 8.58 (s, 
1H), 8.31 (s, 1H), 7.30-7.16 (m, 5H), 6.11 (d, 1H, J= 5.5 Hz), 
4.22-4.10 (m, 1H), 4.00-3.89 (m, 2H), 3.77 (dd, 1H, J= 9.5 4.5 
Hz), 3.49 (dd, 1H, J= 9.5 3.9 Hz), 3.30-3.13 (m, 4H), 2.99-2.79 
(m, 2H), 2.20-2.07 (m, 2H), 1.38 (d, 3H, J= 7.2 Hz), 0.84 (s, 3H), 105 
0.69 (s, 3H); HRMS (EI) Calcd. for C30H43N7O17P3S: 898.1654, 
Found: 898.1640. 
 
Synthesis of R-2-phenylpropanoyl-CoA 8R 
In similar fashion to the preparation of 8S, 8R was obtained from 110 
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the reaction of 9R (30 mg, 0.20 mmol) and coenzyme A, tri-
lithium salt (16 mg, 0.02 mmol) in THF (2 mL) and aq. NaHCO3 
(2 mL, 0.1 M) to give 8R as a colourless solid (2.7 mg). NMR 
and other data were identical to 8S. 
ACOT assays 5 
Human ACOT1 and ACOT2 were expressed as recombinant His-
tag proteins in E. coli BL21 (DE3) pLysS.22 Cells (~2 g) were 
lysed using Bugbuster (Novagen) in the presence of Benzonase 
and enzyme purified by metal-chelate chromatography. Purified 
enzyme was exchanged into 20 mM HEPES-NaOH, pH 7.27 and 10 
protein concentrations determined by UV-visible spectrometry. 
Protein purity was ca. 95 – 98 % by SDS-PAGE analyses. 
 Assays contained 0.109 mg (2.27 nmol) of ACOT1 or 0.099 
mg (1.80 nmol) of ACOT2. Reactions were carried out at pH 
7.27,22 as this minimises spontaneous hydrolysis of DTNB.46 The 15 
following substrates (Tables 1 and 2) were used in the assays: 
Myristoyl-CoA 11 (known substrate for ACOT enzymes22, 32); S-
2-hydroxy-2-phenylacetyl-CoA 2S; R-2-hydroxy-2-phenylacetyl-
CoA 2R; S-2-phenylpropanoyl-CoA 8S; and R-2-
phenylpropanoyl-CoA 8R. Stock concentrations of acyl-CoA 20 
esters were determined using 1H NMR.21 Solutions of acyl-CoA 
esters were diluted in HEPES-NaOH, pH 7.27 except for 
myristoyl-CoA 11 where buffer was supplemented with BSA as 
previously described.22 This was required to reduce substrate 
inhibition due to the formation of micelles. Kinetic analyses of 11 25 
with ACOT1 and ACOT2 used substrate concentrations of 2 – 60 
μM. All other kinetic analyses used concentrations of 5 – 200 
μM. Assays were initiated by addition of enzyme (50 µL) to 
substrate: DTNB (2 x stock solution) and the reaction monitored 
for up to 15 minutes. Rates at each substrate concentration were 30 
measured using three dependent repeats. Reaction rates were 
obtained by plotting changes in absorbance for the linear progress 
curve with Excel. Activities in nmol.min.-1mg-1 were calculated 
assuming ε412 = 14.15 mM-1 cm-1 at 25 ºC.46, 47  
 Data was analysed using SigmaPlot 11 and enzyme kinetics 35 
module 1.3, fitting to the Michaelis-Menten equation with and 
without uncompetitive substrate inhibition. The correct model 
was chosen based on convergence of fitting and visual inspection 
of plots. Kinetic plots for all substrates are available in 
Supplementary Information. Km, Ki and Vmax values are reported 40 
in Tables 1 and 2 as mean values ± SE. Ki values are reported for 
those substrates showing substrate inhibition. 
AMACR assays 
Human AMACR was expressed in E. coli Rosetta2 (DE3) grown 
at 37 °C and 220 r.p.m. until an O.D.600 = ~1.5 was reached. 45 
Cultures were cooled to 22 °C, induced with 0.25 mM IPTG and 
incubated overnight under the same conditions.21 Cells (~2 g) 
were lysed using the ‘one shot’ (Constant Systems) in ~30 mL 
NaH2PO4-NaOH, 300 mM NaCl and 10 mM imidazole pH 7.2, 
supplemented with 1 mM PMSF, 1 mM benzamidine-HCl, and 50 
250 u Benzonase (Novagen) and stirred with N-lauroyl-sarcosine 
[1.5% (w/v)] at 4 °C for 1 hour. The sample was centrifuged 
(Beckmann JA-14 rotor, 10,000 r.p.m., 15,300 g, 10 minutes), 
filtered through a 0.45 µ filter, and purified by metal-chelate 
chromatography as previously described.26 Purified enzyme was 55 
dialysed into 20 mM NaH2PO4-NaOH, pH 7.4 and stored at -80 
°C. Protein concentration was determined by UV-visible 
spectroscopy.21 Protein purity of pooled fractions was ca. 95 – 98 
% by SDS-PAGE analyses. 
 Assays were conducted in 50 mM NaH2PO4-NaOH buffer, pH 60 
7.4 containing ca. 85% (v/v) 2H2O, 100 µM acyl-CoA substrate 
and 3.5 µM enzyme as previously described,21, 26, 27 with negative 
controls containing heat-inactivated enzyme. ±-Fenoprofenoyl-
CoA, an Ibuprofenoyl-CoA analogue and the best AMACR 
substrate reported to date,21 was used as a positive control in all 65 
assays. Stock concentrations of acyl-CoA esters were determined 
using 1H NMR.21 Assays were initiated by addition of enzyme to 
the substrate in buffer, which were incubated at 30 °C for 1 hour. 
After this time samples were heated at 50 °C for 10 minutes to 
inactivate the enzyme and analysed by 1H NMR (500.13 MHz). 70 
Conversion of 2-phenylpropanoyl-CoA substrates 8S and 8R was 
quantified by conversion of the 2-Me doublet at ca. 1.0 p.p.m. 
into a single peak, a 1:1:1 triplet with J = ~1 Hz, as previously 
described for other substrates.21, 26 Conversion of 2-hydroxy-2-
phenylacetyl-CoA 2S and 2R was monitored by reduction of the 75 
α-proton singlet at ca. 5.3 p.p.m. due to deuterium incorporation. 
Acknowledgements 
This work was funded by Prostate Cancer UK. Part of this work 
was performed as a Masters in Pharmacy final year project at the 
University of Bath, U.K.  MJ, MDT, TJW and MDL are members 80 
of the Cancer Research @ Bath network. 
Notes and references 
Medicinal Chemistry, Department of Pharmacy & Pharmacology, 
University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom *E-
mail: M.D.Lloyd@bath.ac.uk; +-44-1225-386786. 85 
†Electronic Supplementary Information (ESI) available: Substrate NMR 
and mass spectra data, NMR spectra of substrates incubated with 
AMACR and kinetic plots of substrates of ACOT enzymes. See 
DOI: 10.1039/b000000x/ 
‡Abbreviations used: ACOT, acyl-CoA thioesterase; AMACR, α-90 
methylacyl-CoA racemase (a.k.a. P504S); 2-APAs, 2-arylpropanoic acids 
(‘profens’); BSA, bovine serum albumin; tBu, tert-butyl; CoA-SH, 
coenzyme A (reduced form); CYP2E1, cytochrome P450 2E1; DTNB, 
5,5′-Dithiobis(2-nitrobenzoic acid); E. coli, Escherichia coli; ESI-TOF, 
electrospray ionisation-time-of-flight; HEPES, 4-(2-95 
hydroxyethyl)piperazine-1-ethanesulfonic acid; kcat, 1
st order rate constant 
for conversion of substrate to product; kcat/Km, selectivity constant; Ki, 
inhibitor constant; Km, Michaelis constant; Mandelic acid, 2-hydroxy-2-
phenylacetic acid; O.D.600, optical density at 600 nm; NAD+, 
nicotinamide adenine dinucleotide (oxidised form) NMR, nuclear 100 
magnetic resonance; PMSF, phenylmethylsulfonyl fluoride; p.p.m., parts 
per million; r.p.m., revolutions per minute; SDS-PAGE, sodium dodecyl 
sulfate polyacrylamide gel electrophoresis; SE, standard error; TBDMS-
Cl, tert-Butyldimethylsilyl chloride; THF, tetrahydrofuran. Vmax, 
maximum rate of enzyme reaction. 105 
 
1. J.-K. Chung, W. Yuan, G. Liu and J. Zheng, Toxicology, 2006, 226, 
99-106. 
2. S. F. Helal and W. S. Elshafy, Toxicol. Ind. Health, 2013, 29, 812-
819. 110 
3. L. Drummond, J. Caldwell and H. K. Wilson, Xenobiotica, 1989, 19, 
199-207. 
4. L. Drummond, J. Caldwell and H. K. Wilson, Xenobiotica, 1990, 20, 
159-168. 
5. I. Linhart, I. Gut, J. Smejkal and J. Novak, Chem. Res. Toxicol., 115 
2000, 13, 36-44. 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  7 
6. L.-B. Gao, J.-Z. Wang, T.-W. Yao and S. Zeng, Chirality, 2012, 24, 
86-95. 
7. M. Polakova, Z. Krajcovicova, V. Melus, M. Stefkovicova and M. 
Sulcova, Cent. Euro. J. Pub. Health, 2012, 20, 226-232. 
8. G. Terre'Blanche, N. Heyer, J. J. Bergh, L. J. Mienie, C. J. van der 5 
Schyf and B. H. Harvey, Neurotox. Res., 2011, 20, 97-101. 
9. V. K. Garg, S. Sinha and R. Sarkar, Dermatologic Surgery, 2009, 35, 
59-65. 
10. B. C. Herold, I. Scordi-Bello, N. Cheshenko, D. Marcellino, M. 
Dzuzelewski, F. Francois, R. Morin, V. M. Casullo, R. A. Anderson, C. 10 
Chany, D. P. Waller, L. J. D. Zaneveld and M. E. Klotman, J. Virol., 
2002, 76, 11236-11244. 
11. M. J. Keller, M. E. Klotman and B. C. Herold, J. Antimicrob. 
Chemother., 2003, 51, 1099-1102. 
12. P. M. M. Mesquita, S. S. Wilson, P. Manlow, L. Fischetti, M. J. 15 
Keller, B. C. Herold and R. J. Shattock, J. Virol., 2008, 82, 6576-6584. 
13. L. J. D. Zaneveld, R. A. Anderson, X. H. Diao, D. P. Waller, C. 
Chany, K. Feathergill, G. Doncel, M. D. Cooper and B. Herold, Fertility 
and Sterility, 2002, 78, 1107-1115. 
14. O. Kuisle, E. Quinoa and R. Riguera, J. Org. Chem., 1999, 64, 8063-20 
8075. 
15. S. S. Hall, L. M. Doweyko, A. M. Doweyko and J. S. R. Zilenovski, 
J. Med. Chem., 1977, 20, 1239-1242. 
16. T. Fukuda, H. Ito, T. Mukainaka, H. Tokuda, H. Nishino and T. 
Yoshida, Biol. Pharmaceut. Bull., 2003, 26, 271-273. 25 
17. R. N. Armstrong, Biochemistry, 2000, 39, 13625-13632. 
18. B. Mitra, A. T. Kallarakal, J. W. Kozarich, J. A. Gerlt, J. G. Clifton, 
G. A. Petsko and G. L. Kenyon, Biochemistry, 1995, 34, 2777-2787. 
19. M. St. Maurice and S. L. Bearne, Biochemistry, 2000, 39, 13324-
13335. 30 
20. M. D. Lloyd, M. Yevglevskis, G. L. Lee, P. J. Wood, M. D. 
Threadgill and T. J. Woodman, Prog. Lipid Res., 2013, 52, 220-230. 
21. T. J. Woodman, P. J. Wood, A. S. Thompson, T. J. Hutchings, G. R. 
Steel, P. Jiao, M. D. Threadgill and M. D. Lloyd, Chem. Commun., 2011, 
47, 7332-7334. 35 
22. X. Qu, A. Allan, G. Chui, T. J. Hutchings, P. Jiao, L. Johnson, W. Y. 
Leung, P. K. Li, G. R. Steel, A. S. Thompson, M. D. Threadgill and M. D. 
Lloyd, Biochem. Pharmacol., 2013, 86, 1621–1625. 
23. R. Brugger, B. G. Alia, C. Reichel, R. Waibel, S. Menzel, K. Brune 
and G. Geisslinger, Biochem. Pharmacol., 1996, 52, 1007-1013. 40 
24. R. Brugger, C. Reichel, B. G. Alia, K. Brune, T. Yamamoto, I. 
Tegeder and G. Geissinger, Biochem. Pharmacol., 2001, 61, 651-656. 
25. C. Sevoz, E. Benoît and T. Buronfosse, Drug Metab. Disposit., 2000, 
28, 398-402. 
26. D. J. Darley, D. S. Butler, S. J. Prideaux, T. W. Thornton, A. D. 45 
Wilson, T. J. Woodman, M. D. Threadgill and M. D. Lloyd, Org. Biomol. 
Chem., 2009, 7, 543-552. 
27. F. A. Sattar, D. J. Darley, F. Politano, T. J. Woodman, M. D. 
Threadgill and M. D. Lloyd, Chem. Commun., 2010, 46, 3348-3350. 
28. L. Amery, M. Fransen, K. De Nys, G. P. Mannaerts and P. P. Van 50 
Veldhoven, J. Lipid Res., 2000, 41, 1752-1759. 
29. S. Ferdinandusse, S. Denis, L. Ijlst, G. Dacremont, H. R. Waterham 
and R. J. A. Wanders, J. Lipid Res., 2000, 41, 1890-1896. 
30. T. J. Kotti, K. Savolainen, H. M. Helander, A. Yagi, D. K. Novikov, 
N. Kalkkinen, E. Conzelmann, J. K. Hiltunen and W. Schmitz, J. Biol. 55 
Chem., 2000, 275, 20887-20895. 
31. M. C. Hunt, J. Yamada, L. J. Maltais, M. W. Wright, E. J. Podesta 
and S. E. H. Alexson, J. Lipid Res., 2005, 46, 2029-2032. 
32. M. C. Hunt, A. Rautanen, M. A. K. Westin, L. T. Svensson and S. E. 
H. Alexson, FASEB J., 2006, 20, 1855-1864. 60 
33. K. Savolainen, P. Bhaumik, W. Schmitz, T. J. Kotti, E. Conzelmann, 
R. K. Wierenga and J. K. Hiltunen, J. Biol. Chem., 2005, 280, 12611-
12620. 
34. P. Bhaumik, W. Schmitz, A. Hassinen, J. K. Hiltunen, E. 
Conzelmann and R. K. Wierenga, J. Mol. Biol., 2007, 367, 1145-1161. 65 
35. S. Sharma, P. Bhaumik, W. Schmitz, R. Venkatesan, J. K. Hiltunen, 
E. Conzelmann, A. H. Juffer and R. K. Wierenga, J. Phys. Chem. B, 2012, 
116, 3619-3629. 
36. Y. Chiang, A. J. Kresse, P. Pruszynski, N. P. Schepp and J. Wirz, 
Angew. Chem. Int. Ed. Eng., 1990, 29, 792-794. 70 
37. J. P. Richard and T. L. Amyes, Curr. Opin. Chem. Biol., 2001, 5, 
626-633. 
38. L. Shi, P. Gao, X.-X. Yan and D.-C. Liang, Proteins-Struct. Funct. 
Bioinform., 2009, 77, 994-999. 
39. A. A. McCarthy, H. M. Baker, S. C. Shewry, M. L. Patchett and E. 75 
N. Baker, Structure, 2001, 9, 637-646. 
40. P. A. Watkins, D. Maiguel, Z. Jia and J. Pevsner, J. Lipid Res., 2007, 
48, 2736-2750. 
41. V. Foulon, M. Sniekers, E. Huysmans, S. Asselberghs, V. Mahieu, G. 
P. Mannaerts, P. P. Van Veldhoven and M. Casteels, J. Biol. Chem., 80 
2005, 280, 9802-9812. 
42. L. A. Paige, G. Q. Zheng, S. A. Defrees, J. M. Cassady and R. L. 
Geahlen, Biochemistry, 1990, 29, 10566-10573. 
43. L.-B. Gao, J.-Z. Wang and S. Zeng, Acta Pharmaceutic. Sinica, 2009, 
44, 778-784. 85 
44. S. Angermüller, C. Leupold, K. Zaar and H. D. Fahimi, 
Histochemistry, 1986, 85, 411-418. 
45. L.-B. Gao, J.-Z. Wang, T.-W. Yao and S. Zeng, Zhongguo Yaolixue 
Yu Dulixue Zazhi, 2009, 23, 351-356. 
46. P. W. Riddles, R. L. Blakeley and B. Zerner, Anal. Biochem., 1979, 90 
94, 75-81    
47. P. Eyer, F. Worek, D. Kiderlen, G. Sinko, A. Stuglin, V. Simeon-
Rudolf and E. Reiner, Anal. Biochem., 2003, 312, 224-227. 
 
 95 
